Bas Havekes
Maastricht University Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bas Havekes as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:51 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT01379898 · Phenoxybenzamine Versus Doxazosin in PCC PatientsUniversity Medical Center Groningen · completed · Pheochromocytoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:51 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans.Am J Clin Nutr · 2020137 citationsRCR 6.6
- Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans.Diabetes · 2015117 citationsRCR 3.8
- Three weeks of time-restricted eating improves glucose homeostasis in adults with type 2 diabetes but does not improve insulin sensitivity: a randomised crossover trial.Diabetologia · 202299 citationsRCR 7.9
- Insulin-mediated suppression of lipolysis in adipose tissue and skeletal muscle of obese type 2 diabetic men and men with normal glucose tolerance.Diabetologia · 201372 citationsRCR 2.2
- 64 citationsRCR 2.5
- 64 citationsRCR 3.0
- 64 citationsRCR 3.3
- Exercise training reduces intrahepatic lipid content in people with and people without nonalcoholic fatty liver.Am J Physiol Endocrinol Metab · 201851 citationsRCR 2.2
- Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial.Diabetes Care · 202148 citationsRCR 2.8
- No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial.Am J Clin Nutr · 202045 citationsRCR 2.9